Evidence map›Paper›PMID 24074390›Full record

ReviewNanomedicine (London, England)2013

Thermal potentiation of chemotherapy by magnetic nanoparticles.

Madeline Torres-Lugo, Carlos Rinaldi

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed.

  1. Nanoparticles: An Emerging Hope in Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2026
    Review
  2. Biomaterials Empowering in New Era of Women's Healthcare System.Reproductive sciences (Thousand Oaks, Calif.) · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Neurosurgical Applications of Magnetic Hyperthermia Therapy.Neurosurgery clinics of North America · 2023
    Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Magnetic Nanoparticle Composites: Synergistic Effects and Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021
    Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Madeline Torres-LugoDepartment of Chemical Engineering, University of Puerto Rico, Mayaguez Campus, PO BOX 9000, Mayaguez, PR 00681, Puerto Rico. madeline@ece.uprm.edu.
Carlos Rinaldi

Funding

UPR/MDACC Partnership for Excellence in Cancer Research (Luis Segarra supplement)U54CA096300 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Larkin Strong · 2002 to 2026
$23.8M
NCI NIH HHS U54 CA096300
6 · The paper itself

Abstract

Clinical studies have demonstrated the effectiveness of hyperthermia as an adjuvant for chemotherapy and radiotherapy. However, significant clinical challenges have been encountered, such as a broader spectrum of toxicity, lack of patient tolerance, temperature control and significant invasiveness. Hyperthermia induced by magnetic nanoparticles in high-frequency oscillating magnetic fields, commonly termed magnetic fluid hyperthermia, is a promising form of heat delivery in which thermal energy is supplied at the nanoscale to the tumor. This review discusses the mechanisms of heat dissipation of iron oxide-based magnetic nanoparticles, current methods and challenges to deliver heat in the clinic, and the current work related to the use of magnetic nanoparticles for the thermal-chemopotentiation of therapeutic drugs.

Indexed as

Chemotherapy, AdjuvantFerric CompoundsHumansHyperthermia, InducedMagnetite NanoparticlesModels, TheoreticalNeoplasmsTemperatureFerric Compoundsferric oxideMagnetite Nanoparticles

Identifiers

PMID24074390
PMCPMC4001113

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.